Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19
| Autor: | John C. O’Horo, M. Rizwan Sohail, Zachary A Yetmar, Andrew D. Badley, Douglas W. Challener, Imad M. Tleyjeh, James R. Cerhan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Medicine (General) Statin medicine.drug_class CAD coronary artery disease 030204 cardiovascular system & hematology Logistic regression Article Odds CHF congestive heart failure 03 medical and health sciences 0302 clinical medicine R5-920 OR odds Ratio DM diabetes mellitus Internal medicine Diabetes mellitus Medicine 030212 general & internal medicine RR risk ratio business.industry Retrospective cohort study CAP community-acquired pneumonia Odds ratio 10-CCI 10-year probability of survival based on the Charlton Comorbidity Index medicine.disease Confidence interval Relative risk CI confidence Interval business |
| Zdroj: | Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 442-446 (2021) Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
| ISSN: | 2542-4548 |
| Popis: | Objective To determine the association between chronic statin use and mortality in patients hospitalized with coronavirus disease 2019 (COVID-19). Patients and Methods We identified a retrospective cohort of patients requiring admission at the Mayo Clinic using our enterprise-wide COVID-19 registry from March 1, 2020, through September 30, 2020. Available information included age, sex, use of statins, medical comorbidities, and 30-day mortality. We estimated the association of statins with 30-day mortality using odds ratios and 95% CIs from logistic regression modeling. Results Patients (N=1295) between the ages of 30 and 80 years tested positive for COVID-19 and required admission during the study period, of whom 500 (38.6%) were taking statins at admission. Patients taking statins were older and more likely to have diabetes mellitus or congestive heart failure. Within 30 days of diagnosis, 59 (4.6%) died. In multivariable analysis, statin users did not have statistically different odds of death within 30 days with an odds ratio of 1.14 (95% CI, 0.64 to 2.03; P=.67) compared to nonusers. Conclusion Patients with COVID-19 taking statins had similar 30-day mortality to those not taking statins after adjusting for relevant covariates. Although this is partly influenced by a higher prevalence of risk factors for more severe COVID-19 presentation not entirely adjusted for by the Charlson comorbidity index, these data would not support statins as a likely therapeutic intervention for COVID-19 in the hospital setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|